Main variables;No. of employees;Total
No. of companies carrying out R&D in Biotechnology;Fewer than 250 employees;1,226
No. of companies carrying out R&D in Biotechnology;250 or more employees;122
No. of companies carrying out R&D in Biotechnology;Total 2021;1,348
%Companies according to biotechnology used: Genetic code;Fewer than 250 employees;30.5
%Companies according to biotechnology used: Genetic code;250 or more employees;36.0
%Companies according to biotechnology used: Genetic code;Total 2021;31.0
%Companies according to biotechnology used: Functional units;Fewer than 250 employees;37.6
%Companies according to biotechnology used: Functional units;250 or more employees;46.7
%Companies according to biotechnology used: Functional units;Total 2021;38.4
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Fewer than 250 employees;20.5
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;250 or more employees;33.6
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Total 2021;21.7
%Companies according to biotechnology used: Bioprocesses;Fewer than 250 employees;48.6
%Companies according to biotechnology used: Bioprocesses;250 or more employees;68.1
%Companies according to biotechnology used: Bioprocesses;Total 2021;50.3
%Companies according to biotechnology used: Sub-cellular organisms;Fewer than 250 employees;7.2
%Companies according to biotechnology used: Sub-cellular organisms;250 or more employees;18.0
%Companies according to biotechnology used: Sub-cellular organisms;Total 2021;8.2
%Companies according to biotechnology used: Bio-computing;Fewer than 250 employees;24.0
%Companies according to biotechnology used: Bio-computing;250 or more employees;25.4
%Companies according to biotechnology used: Bio-computing;Total 2021;24.1
%Companies according to biotechnology used: Nanobiotechnology;Fewer than 250 employees;11.8
%Companies according to biotechnology used: Nanobiotechnology;250 or more employees;11.5
%Companies according to biotechnology used: Nanobiotechnology;Total 2021;11.8
%Companies according to biotechnology used: Other;Fewer than 250 employees;17.0
%Companies according to biotechnology used: Other;250 or more employees;10.7
%Companies according to biotechnology used: Other;Total 2021;16.4
Companies in which biotechnology activities are: Main and/or exclusive;Fewer than 250 employees;639
Companies in which biotechnology activities are: Main and/or exclusive;250 or more employees;22
Companies in which biotechnology activities are: Main and/or exclusive;Total 2021;661
Companies in which biotechnology activities are: A secondary line of business;Fewer than 250 employees;166
Companies in which biotechnology activities are: A secondary line of business;250 or more employees;22
Companies in which biotechnology activities are: A secondary line of business;Total 2021;188
Companies in which biotechnology activities are: A tool necessary for production;Fewer than 250 employees;421
Companies in which biotechnology activities are: A tool necessary for production;250 or more employees;78
Companies in which biotechnology activities are: A tool necessary for production;Total 2021;500
%Company by field(s) of ultimate application of biotechnology use: Human Health;Fewer than 250 employees;45.8
%Company by field(s) of ultimate application of biotechnology use: Human Health;250 or more employees;45.9
%Company by field(s) of ultimate application of biotechnology use: Human Health;Total 2021;45.8
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Fewer than 250 employees;15.6
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;250 or more employees;11.5
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Total 2021;15.3
%Company by field(s) of ultimate application of biotechnology use: Food products;Fewer than 250 employees;31.5
%Company by field(s) of ultimate application of biotechnology use: Food products;250 or more employees;32.0
%Company by field(s) of ultimate application of biotechnology use: Food products;Total 2021;31.5
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Fewer than 250 employees;24.1
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;250 or more employees;19.6
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Total 2021;23.7
%Company by field(s) of ultimate application of biotechnology use: Environment;Fewer than 250 employees;16.0
%Company by field(s) of ultimate application of biotechnology use: Environment;250 or more employees;11.5
%Company by field(s) of ultimate application of biotechnology use: Environment;Total 2021;15.5
%Company by field(s) of ultimate application of biotechnology use: Industry;Fewer than 250 employees;13.4
%Company by field(s) of ultimate application of biotechnology use: Industry;250 or more employees;13.1
%Company by field(s) of ultimate application of biotechnology use: Industry;Total 2021;13.4
Personnel in R&D in biotechnology (no. of persons);Fewer than 250 employees;10,473
Personnel in R&D in biotechnology (no. of persons);250 or more employees;5,271
Personnel in R&D in biotechnology (no. of persons);Total 2021;15,744
Personnel in R&D in biotechnology (no. of persons): Research personnel;Fewer than 250 employees;5,914
Personnel in R&D in biotechnology (no. of persons): Research personnel;250 or more employees;2,465
Personnel in R&D in biotechnology (no. of persons): Research personnel;Total 2021;8,380
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel;Fewer than 250 employees;4,558
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel;250 or more employees;2,806
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel;Total 2021;7,364
Personnel in R&D in biotechnology (no. of persons). Women;Fewer than 250 employees;5,482
Personnel in R&D in biotechnology (no. of persons). Women;250 or more employees;3,242
Personnel in R&D in biotechnology (no. of persons). Women;Total 2021;8,725
Personnel in R&D in biotechnology (no. of persons). Women: Research personnel;Fewer than 250 employees;3,094
Personnel in R&D in biotechnology (no. of persons). Women: Research personnel;250 or more employees;1,426
Personnel in R&D in biotechnology (no. of persons). Women: Research personnel;Total 2021;4,521
Personnel in R&D in biotechnology (no. of persons). Women: Technical and auxiliary personnel;Fewer than 250 employees;2,388
Personnel in R&D in biotechnology (no. of persons). Women: Technical and auxiliary personnel;250 or more employees;1,816
Personnel in R&D in biotechnology (no. of persons). Women: Technical and auxiliary personnel;Total 2021;4,204
Personnel in R&D in biotechnology (FTE);Fewer than 250 employees;7,354.4
Personnel in R&D in biotechnology (FTE);250 or more employees;4,168.8
Personnel in R&D in biotechnology (FTE);Total 2021;11,523.2
Personnel in R&D in biotechnology (FTE): Research personnel;Fewer than 250 employees;4,402.9
Personnel in R&D in biotechnology (FTE): Research personnel;250 or more employees;1,938.6
Personnel in R&D in biotechnology (FTE): Research personnel;Total 2021;6,341.6
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel;Fewer than 250 employees;2,951.5
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel;250 or more employees;2,230.1
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel;Total 2021;5,181.6
Personnel in R&D in biotechnology (FTE). Women;Fewer than 250 employees;3,909.3
Personnel in R&D in biotechnology (FTE). Women;250 or more employees;2,643.4
Personnel in R&D in biotechnology (FTE). Women;Total 2021;6,552.7
Personnel in R&D in biotechnology (FTE). Women: Research personnel;Fewer than 250 employees;2,305.8
Personnel in R&D in biotechnology (FTE). Women: Research personnel;250 or more employees;1,158.6
Personnel in R&D in biotechnology (FTE). Women: Research personnel;Total 2021;3,464.4
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel;Fewer than 250 employees;1,603.5
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel;250 or more employees;1,484.8
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel;Total 2021;3,088.3
Internal expenditure on R&D (thousands of euros);Fewer than 250 employees;648,976
Internal expenditure on R&D (thousands of euros);250 or more employees;388,911
Internal expenditure on R&D (thousands of euros);Total 2021;1,037,887
1) By nature of the expense: Current expenses;Fewer than 250 employees;577,758
1) By nature of the expense: Current expenses;250 or more employees;361,713
1) By nature of the expense: Current expenses;Total 2021;939,471
1.1) Remuneration to research personnel;Fewer than 250 employees;213,250
1.1) Remuneration to research personnel;250 or more employees;108,275
1.1) Remuneration to research personnel;Total 2021;321,525
1.2) Remuneration to technical and auxiliary personnel;Fewer than 250 employees;104,359
1.2) Remuneration to technical and auxiliary personnel;250 or more employees;90,297
1.2) Remuneration to technical and auxiliary personnel;Total 2021;194,656
1.3) Other current expenses;Fewer than 250 employees;260,148
1.3) Other current expenses;250 or more employees;163,141
1.3) Other current expenses;Total 2021;423,290
2) By nature of the expense: Capital expenses;Fewer than 250 employees;71,218
2) By nature of the expense: Capital expenses;250 or more employees;27,197
2) By nature of the expense: Capital expenses;Total 2021;98,416
2.1) Land and buildings;Fewer than 250 employees;8,904
2.1) Land and buildings;250 or more employees;1,246
2.1) Land and buildings;Total 2021;10,150
2.2) Equipment and instruments;Fewer than 250 employees;48,703
2.2) Equipment and instruments;250 or more employees;23,835
2.2) Equipment and instruments;Total 2021;72,538
2.3) Acquisition of specific R&D software;Fewer than 250 employees;3,749
2.3) Acquisition of specific R&D software;250 or more employees;1,963
2.3) Acquisition of specific R&D software;Total 2021;5,713
2.4) Otros productos de propiedad intelectual específicos para I+D;Fewer than 250 employees;9,862
2.4) Otros productos de propiedad intelectual específicos para I+D;250 or more employees;153
2.4) Otros productos de propiedad intelectual específicos para I+D;Total 2021;10,015
1.1) By origin of the funds: Own funds;Fewer than 250 employees;428,118
1.1) By origin of the funds: Own funds;250 or more employees;282,919
1.1) By origin of the funds: Own funds;Total 2021;711,037
1.2) By origin of the funds: From companies;Fewer than 250 employees;87,264
1.2) By origin of the funds: From companies;250 or more employees;34,331
1.2) By origin of the funds: From companies;Total 2021;121,595
1.3) By origin of the funds: Public Administration funds;Fewer than 250 employees;81,113
1.3) By origin of the funds: Public Administration funds;250 or more employees;26,309
1.3) By origin of the funds: Public Administration funds;Total 2021;107,422
1.4) By origin of the funds: From Universities;Fewer than 250 employees;192
1.4) By origin of the funds: From Universities;250 or more employees;0
1.4) By origin of the funds: From Universities;Total 2021;192
1.5) By origin of the funds: From non profit private institutions;Fewer than 250 employees;1,543
1.5) By origin of the funds: From non profit private institutions;250 or more employees;9,213
1.5) By origin of the funds: From non profit private institutions;Total 2021;10,756
1.6) By origin of the funds: Foreign funds;Fewer than 250 employees;50,745
1.6) By origin of the funds: Foreign funds;250 or more employees;36,139
1.6) By origin of the funds: Foreign funds;Total 2021;86,884
Purchase of R&D services in biotechnology (thousands of euros);Fewer than 250 employees;77,001
Purchase of R&D services in biotechnology (thousands of euros);250 or more employees;68,440
Purchase of R&D services in biotechnology (thousands of euros);Total 2021;145,440
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Fewer than 250 employees;54,755
Purchase of R&D services in biotechnology (thousands of euros): In Spain;250 or more employees;41,115
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Total 2021;95,870
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Fewer than 250 employees;22,246
Purchase of R&D services in biotechnology (thousands of euros): Abroad;250 or more employees;27,324
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Total 2021;49,570
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Fewer than 250 employees;41.6
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;250 or more employees;21.3
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Total 2021;39.8
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Fewer than 250 employees;12.5
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;250 or more employees;12.3
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Total 2021;12.5
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Fewer than 250 employees;18.8
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;250 or more employees;14.8
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Total 2021;18.5
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Fewer than 250 employees;10.9
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;250 or more employees;14.8
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Total 2021;11.2
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Fewer than 250 employees;15.9
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;250 or more employees;12.3
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Total 2021;15.6
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;Fewer than 250 employees;17.0
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;250 or more employees;11.5
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;Total 2021;16.5
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Fewer than 250 employees;16.3
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;250 or more employees;13.9
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Total 2021;16.1
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Fewer than 250 employees;40.8
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;250 or more employees;32.8
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Total 2021;40.0
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Fewer than 250 employees;54.9
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;250 or more employees;43.4
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Total 2021;53.9
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Fewer than 250 employees;21.7
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;250 or more employees;18.8
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Total 2021;21.5
% Companies with income of an international origin related to biotechnological activities;Fewer than 250 employees;22.8
% Companies with income of an international origin related to biotechnological activities;250 or more employees;16.4
% Companies with income of an international origin related to biotechnological activities;Total 2021;22.2
% Turnover representing income of an international origin related to biotechnological activities;Fewer than 250 employees;9.1
% Turnover representing income of an international origin related to biotechnological activities;250 or more employees;0.8
% Turnover representing income of an international origin related to biotechnological activities;Total 2021;1.9
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;Fewer than 250 employees;57.9
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;250 or more employees;78.0
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;Total 2021;65.5
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;Fewer than 250 employees;42.1
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;250 or more employees;22.0
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;Total 2021;34.5
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Fewer than 250 employees;93.7
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;250 or more employees;74.2
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Total 2021;86.3
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Fewer than 250 employees;5.2
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;250 or more employees;23.6
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Total 2021;12.2
% Income of an international origin related with activities according to the classification: Operating source abroad;Fewer than 250 employees;0.5
% Income of an international origin related with activities according to the classification: Operating source abroad;250 or more employees;2.1
% Income of an international origin related with activities according to the classification: Operating source abroad;Total 2021;1.1
% Income of an international origin related with activities according to the classification: Other;Fewer than 250 employees;0.6
% Income of an international origin related with activities according to the classification: Other;250 or more employees;0.0
% Income of an international origin related with activities according to the classification: Other;Total 2021;0.4